Johnson & Johnson recently announced it appointed Dr. John Reed as executive vice president of pharmaceuticals, research & development, effective April 3.
Reed most recently served as executive vice president, global head of research & development for Sanofi, where he was responsible for the company’s R&D transformation. He brings more than 35 years of biomedical research leadership to the New Brunswick-based company.
Reed will assume responsibility for the company’s industry-leading portfolio from Dr. William Hait, who has served as interim head of Johnson & Johnson’s pharmaceutical R&D organization since August 2022.
“Dr. Reed is an accomplished leader and highly regarded researcher with an extraordinary track record for discovering and developing life-saving innovations on a global scale,” Joaquin Duato, chairman and CEO of Johnson & Johnson, commented. “I am confident his experience and leadership will enable our pharmaceutical R&D organization to continue to accelerate innovation and competitiveness, invest with focus and discipline and improve the lives of the patients we serve around the world with transformational medicines.”
“I am deeply honored and extremely excited to join Johnson & Johnson. I share the company’s commitment to innovation to conquer disease and improve human health, and I look forward to applying my passion for science, experience in drug discovery and development and commitment to helping patients in leading the talented pharmaceutical R&D team,” Reed said.
Prior to Sanofi, Reed served as global head of pharmaceutical research & early development at Roche, where he was also a member of the company’s Executive Committee, and CEO of a large, independent, nonprofit biomedical research institute in La Jolla, California.
Reed has authored more than 900 research publications and invented over 130 patents. He was recognized among the Top 10 most cited researchers in life sciences and medicine for a decade and still ranks among the world’s Top 100 most highly cited scientists.
